Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

華控康泰集團有限公司
Kontafarma China Holdings Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1312)

PROPOSED CHANGE OF COMPANY ENGLISH NAME

The board (the "**Board**") of directors (the "**Directors**") of Kontafarma China Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") proposes to change the English name of the Company from "Kontafarma China Holdings Limited" to "Kontafarma Holdings Limited" and the dual foreign name in Chinese of the Company will remain unchanged as "華控康泰集團有限公司" (the "**Proposed Change of Company English Name**").

CONDITIONS FOR THE PROPOSED CHANGE OF COMPANY ENGLISH NAME

The Proposed Change of Company English Name is subject to the following conditions:

(i) the passing of a special resolution by the shareholders of the Company (the "**Shareholders**") at an extraordinary general meeting of the Company (the "**EGM**") to be convened to approve the Proposed Change of Company English Name; and

(ii) the Registrar of Companies in the Cayman Islands approving the Proposed Change of Company English Name.

Subject to the satisfaction of the above conditions, the Proposed Change of Company English Name will take effect from the date on which the Registrar of Companies in the Cayman Islands enters the new English name in the register of companies in place of the current English name of the Company, and issues a certificate of incorporation on change of name. Thereafter, the Company will comply with the necessary filing or registration procedures with the Companies Registry in Hong Kong under the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) and the Cayman Islands.

REASONS FOR THE PROPOSED CHANGE OF COMPANY ENGLISH NAME

As disclosed in the announcement of the Company dated 10 September 2026 and the circular of the Company dated 24 September 2026, creditors' voluntary winding-up (the "**CVL**") of subsidiaries of the Company which operated fitness and yoga centres in Singapore has been initiated and urging for the cessation of operation of such fitness and yoga centres. Prior to the CVL, the Group engaged in operating of fitness centres and provision of consultation services for fitness and health activities, and operating of franchise business for royalty fee income in addition to its current principal business in manufacturing and sales of drugs in the People's Republic of China, including chemical drugs, active pharmaceutical ingredients ("**API**") and API intermediate.

In light of the above, the Group is currently placing greater focus on its pharmaceutical business, with Beijing (focusing on gynecological drugs and topical anesthetics) and Chongqing (focusing on API and pharmaceutical intermediates) serving as the core operating entities of its two major production bases. Through a decade of deep cultivation in the pharmaceutical sector since 2016, its API products have expanded from the domestic market to the global stage, reaching multiple overseas markets including Europe, the United States, Japan, and South Korea etc.. The relevant product varieties have obtained numerous international pharmaceutical market access qualifications, such as the World Health Organization Prequalification (WHO-PQ), the U.S. Food and Drug Administration (FDA), Pharmaceuticals and Medical Devices Agency (PMDA), the European Directorate for the Quality of Medicines & HealthCare (EDQM), and Ministry of Food and Drug Safety (MFDS) etc., thereby establishing a solid foundation for the Group's further global expansion.

Under these circumstances, the proposed new English name, "Kontafarma Holdings Limited", is more concise. By removing the term "China" which merely serves as a geographical limitation, the name aligns better with the Group's positioning as a pharmaceutical holding company. This avoids market misconception that the Group's products and operations are restricted to the Chinese market and helps the Group establish a clear and unified corporate image for international procurement and overseas registration.

Meanwhile, the dual foreign name in Chinese of the Company will remain unchanged as "華控康泰集團有限公司", where "華控" will continue to highlight the Group's corporate origins and brand legacy. The business strategies, management structure, and day-to-day operations of the Group will not undergo any changes as a result of the Proposed Change of Company English Name.

Based on the above reasons, the Board believes that the Proposed Change of Company English Name is intended to precisely reflect the Group's business substance, market reach of its products, strategic positioning and future development direction and is in the interests of the Company and the Shareholders as a whole.

EFFECTS OF THE PROPOSED CHANGE OF COMPANY ENGLISH NAME

The Proposed Change of Company English Name will not affect any rights of the existing Shareholders or the Group's daily business operations or financial position. All existing share certificates of the Company in issue bearing the existing name of the Company will, after the Proposed Change of Company English Name becoming effective, continue to be evidence of title to the share(s) of the Company (the "**Shares**") and will remain valid for trading, settlement, registration and delivery purposes. Accordingly, there will not be any arrangement for free exchange of existing share certificates of the Company for new share certificates bearing the new name of the Company. Once the Proposed Change of Company English Name becomes effective, new share certificates of the Company will be issued only in the new name of the Company.

Subject to the confirmation of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**"), the English stock short name of the Company for trading in the Shares will be changed, if necessary, after the Proposed Change of Company English Name becomes effective.

GENERAL

Special resolutions will be proposed at the EGM for Shareholders to consider and, if thought fit, approve the Proposed Change of Company English Name. A circular containing, among other things, (i) details of the Proposed Change of Company English Name; and (ii) the notice of the EGM, together with a proxy form will be despatched to the Shareholders in due course.

To the best of the Directors' knowledge, information and belief, and having made all reasonable enquiries, no Shareholder will be required to abstain from voting on the resolution to approve the Proposed Change of Company English Name.

The Company will make further announcement(s) to inform the Shareholders of the poll results of the EGM, the effective date of the Proposed Change of Company English Name, the new English stock short name of the Company for trading in the Shares on the Stock Exchange and other relevant information as and when appropriate.

By order of the Board of
Kontafarma China Holdings Limited
Wang Limin
Chairman

Hong Kong, 20 November 2026

As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Wang Limin (Chairman), Mr. Li Qingshan (President), Mr. Ge Shouwen (Vice President), and Ms. Guo Zixiu (Financial Controller); and three independent non-executive Directors, namely Dr. Tang Lai Wah, Dr. Ho Ho Ming and Mr. Yao Xiaomin.